Jazz Pharmaceuticals plc
NASDAQJazz Pharmaceuticals just delivered its strongest quarterly beat in years — and the positioning data shows shorts were already getting out of the way before the numbers hit. Q1 2026 revenue came in at $1.07 billion, up nearly 19% year-on-year. Net income flipped from a $92.5 million loss to $293.1 million profit. Diluted EPS of $4.43 topped prior-year's loss per share of $1.52 by a…
JAZZ short interest drops 24% in a week to 8.8% of float, down from recent peak of over 11% in late April.
Snapshot as of 6 May 2026
Jazz Pharmaceuticals just delivered its strongest quarterly beat in years — and the positioning data shows shorts were already getting out of the way before the numbers hit. Q1 2026 revenue came in at $1.07 billion, up…
Jazz Pharmaceuticals heads into its May 6 Q1 earnings report with short sellers meaningfully on the back foot after a sharp squeeze in late April. The short interest story has been the defining positioning move of the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for JAZZ — free to start on ORTEX.
Sign up for free →Open JAZZ on ORTEX